ajulemic acid
Sign in to saveLenabasum (also known as ajulemic acid, '''1',1'-dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid, DMH-D8-THC-11-OIC, AB-III-56, HU-239, IP-751, CPL 7075, CT-3, JBT-101, Anabasum, and Resunab''') is a synthetic cannabinoid that shows anti-fibrotic and anti-inflammatory effects in pre-clinical studies without causing a subjective "high". Although its design was inspired by a metabolite of delta-9-THC known as delta-9-THC-11-oic acid, lenabasum is an analog of the delta-8-THC metabolite delta-8-THC-11-oic acid. It is being developed for the treatment of inflammatory and fibrotic condition
Research
83 papers- Ajulemic acid: potential treatment for chronic inflammation.Pharmacology research & perspectives · 2018
- Syntheses of Cannabinoid Metabolites: Ajulemic Acid and HU-210.Molecules (Basel, Switzerland) · 2024
- Ajulemic acid.IDrugs : the investigational drugs journal · 2005
- Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials.The AAPS journal · 2005
- Ajulemic acid (CT3): a potent analog of the acid metabolites of THC.Current pharmaceutical design · 2000
via PubMed
Wikidata facts
- Mass
- 400.26135963199994
Show 3 more facts
- chemical formula
- C₂₅H₃₆O₄
- isomeric SMILES
- CCCCCCC(C)(C)c1cc(c2c(c1)OC([C@H]3[C@H]2CC(=CC3)C(=O)O)(C)C)O
- canonical SMILES
- O=C(O)C1=CCC2C(C3=C(O)C=C(C=C3OC2(C)C)C(C)(C)CCCCCC)C1
Sources (2)
via Wikidata · CC0
~2 min read
Article
1 sectionsContents
- References
Lenabasum (also known as ajulemic acid, '''1',1'-dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid, DMH-D8-THC-11-OIC, AB-III-56, HU-239, IP-751, CPL 7075, CT-3, JBT-101, Anabasum, and Resunab''') is a synthetic cannabinoid that shows anti-fibrotic and anti-inflammatory effects in pre-clinical studies without causing a subjective "high". Although its design was inspired by a metabolite of delta-9-THC known as delta-9-THC-11-oic acid, lenabasum is an analog of the delta-8-THC metabolite delta-8-THC-11-oic acid. It is being developed for the treatment of inflammatory and fibrotic conditions such as systemic sclerosis, dermatomyositis and cystic fibrosis. It does not share the anti-emetic effects of some other cannabinoids, but may be useful for treating chronic inflammatory conditions where inflammation fails to resolve. Side effects include dry mouth, tiredness, and dizziness. The mechanism of action is through activation of the CB2 receptor leading to production of specialized proresolving eicosanoids such as lipoxin A4 and prostaglandin J2. Studies in animals at doses up to 40 mg/kg show minimal psychoactivity of lenabasum, compared to that produced by tetrahydrocannabinol. Lenabasum is being developed by Corbus Pharmaceuticals (formerly JB Therapeutics) for the treatment of orphan chronic life-threatening inflammatory diseases. Development since been discontinued.
== References ==